CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Xueying Li, He Huang, Bing Xu, Hongqiang Guo, Yingcheng Lin, Sheng Ye, Jiqun Yi, Wenyu Li, Xiangyuan Wu, Wei Wang, Hongyu Zhan, Derong Xie, Jiewen Peng, Yabing Cao, Xingxiang Pu, Chengcheng Guo, Huangming Hong, Zhao Wang, Xiaojie Fang, Yong Zhou, Suxia Lin, Qing Liu, Tongyu Lin
Cancer Research and Treatment. 2019;51(3):919-932.   Published online 2018 October 2    DOI: https://doi.org/10.4143/crt.2018.230

Excel Download

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Cancer Research and Treatment. 2019;51(3):919-932   Crossref logo
Link1 Link2 Link3

Rituximab Plus CHOP is Superior to CHOP Alone for Aggressive Diffuse Large B-Cell Lymphoma: Interim Results of a GELA Phase III Trial
Clinical Lymphoma. 2001;1(4):257-258   Crossref logo
Link1 Link2

Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma1
Clinical Lymphoma. 2000;1(1):27-28   Crossref logo
Link1 Link2

Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma
Current Oncology Reports. 2003;5(5):357-357   Crossref logo
Link1 Link2 Link3

Rituximab as Consolidation Therapy Did Not Improve Outcome in Patients with Diffuse Large B-Cell Lymphoma at Complete Response After Dose-Dense Chemotherapy (CHOP-14)
Cancer Biotherapy and Radiopharmaceuticals. 2015;30(3):107-110   Crossref logo
Link1 Link2

Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study
Acta Haematologica. 2006;115(1-2):22-27   Crossref logo
Link1 Link2

Intensified 14-Day Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (RCHOP14) Compared to R-CHOP (RCHOP21) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)
Clinical Lymphoma Myeloma and Leukemia. 2018;18:S276-S277   Crossref logo
Link1 Link2

CN2 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB + CHOP VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NONHODGKIN LYMPHOMA
Value in Health. 2004;7(6):643-644   Crossref logo
Link1 Link2

1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Annals of Oncology. 2018;29(suppl_8):   Crossref logo
Link1

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP
Leukemia. 2016;30(8):1799-1800   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.